Investigator: Francisco Moreno, MD
University of Arizona, Tucson, USA
This is the first FDA-approved study in more than 25 years to examine the use of psilocybin in a patient population. The principal investigators plan to study the use of psilocybin in 10 patients suffering from obsessive-compulsive disorder (OCD). They want to determine if they can replicate in a clinical study several published case reports of patients whose OCD symptoms were reduced after self- experimentation with psilocybin mushrooms. MAPS has paid $12,250 for the synthesis of one gram of psilocybin. Analytical data on this psilocybin has been submitted to FDA in March, 2001, with approval obtained from the FDA on May 9, 2001. DEA licenses received July 2, 2001. First patient was treated on November 27, 2001, and after enrolling nine subjects, the study is now complete. Dr. Moreno’s research team is now looking at the data, and a publication will be forthcoming. Preliminary analyses have been performed, and the data has been presented at the Society of Biological Psychiatry, The American College of Neuropsychopharmacology, the New Clinical Drug Evaluation Unit, and the International Transpersonal Association (ITA) Annual Meetings. Current news on this study, Study Protocol, Informed Consent Form
- Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychi 67: 1735-1740.